Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at [email protected].
Latest Media Coverage
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Browse the archive
Handelsblatt
Corona drug search: The pharmaceutical industry sets new priorities
The British analysis company Evaluate Pharma, for example, estimates that the number of interrupted and delayed clinical studies has increased by a factor of 15 compared…
The Pharma Letter
EMA validates tafasitamab regulatory submission
he sell-side expects tafasitamab to generate 2024 revenue of $661 million, according to EvaluatePharma consensus forecasts.
PMLive
FDA gives Roche’s Tecentriq green light for first-line NSCLC
That initial approval in NSCLC helped Keytruda to become the forecasted highest selling drug globally by 2024, with Evaluate Pharma predicting Merck/MSD’s drug will reach…
PMLive
Merck’s Keytruda hits the mark in triple negative breast cancer
Keytruda remains dominant in the anti-PD-1/L1 category, with EvaluatePharma forecasting that sales of the drug will reach $24.3bn in 2026.
Pharmaphorum
FDA clears Lilly’s Retevmo for RET-positive lung, thyroid
EvaluatePharma has said that selpercatinib could become a $500 million-plus product by 2024.
The Pharma Letter
Look back at pharma news in the week to May 8, 2020
Large-scale M&A might be off the table during the COVID-19 pandemic, but Menarini proved last Monday that the day-to-day business of smaller transactions continues,…
The Pharma Letter
Look back at pharma news in the week to May 1, 2020
Evaluate Vantage has been tracking notable COVID-19 announcements, and it is clear that the pandemic news flow is showing no sign of slowing.
El Pais
The Covid-19 vaccine will need the capacity of the big four manufacturers
The biopharmaceutical industry is working at full speed to find a vaccine against the Covid-19 pandemic. There are already almost 89 R&D projects to find that…
El Global
Covid-19: 230 clinical trials with 196,230 patients worldwide
Efforts to research or develop a drug that helps fight SARS-CoV-2 are titanic. And so shows a report recently published by the consultant Evaluate Pharma. This study…
FiercePharma
Immunomedics finally wins its blockbuster FDA nod for Trodelvy in triple-negative breast cancer
Also known as sacituzumab govitecan, the drug won accelerated FDA nod as a third-line treatment for metastatic triple-negative breast cancer more than a month ahead of…